BeiGene and Revolution Medicines Forge Strategic Partnership to Bring Breakthrough Pancreatic Cancer Therapy to Asia
核心洞察
BeiGene (搜索) entered a clinical development and commercialization partnership with Revolution Medicines, gaining exclusive rights to four RAS (搜索)(ON) inhibitors across Asian markets covering approximately 2 billion people.
The lead asset daraxonrasib demonstrated a near-doubling of median survival in advanced pancreatic cancer (搜索), extending it from 6.7 months to 13.2 months in Phase 3 data presented at ASCO.
The FDA accepted daraxonrasib's New Drug Application on July 22 for previously treated metastatic pancreatic ductal adenocarcinoma, potentially making it the first effective RAS (搜索)-targeted therapy in this indication.
BeiGene (搜索) saw its A-shares and Hong Kong-listed shares surge over 4% in early trading on August 11, with its A-share market capitalization briefly topping CNY 482 billion (approximately $71.5 billion), following the announcement of a major clinical development and regional commercialization partnership with U.S. biotech Revolution Medicines.
The collaboration grants BeiGene (搜索) exclusive rights to develop and commercialize four of Revolution Medicines' RAS (搜索)(ON) inhibitors in Asian markets with a combined population of approximately 2 billion, including China, Indonesia, the Philippines, Malaysia, New Zealand, Thailand, and Vietnam. The deal also encompasses a clinical collaboration exploring combination therapy potential between BeiGene's oncology candidates and Revolution Medicines' RAS-targeting assets.
Daraxonrasib: A Potential Turning Point in Pancreatic Cancer (搜索)
The most closely watched asset in the deal is daraxonrasib, a drug candidate that generated significant attention at this year's American Society of Clinical Oncology (ASCO) annual meeting. Phase 3 clinical trial data for advanced pancreatic cancer (搜索) showed the therapy significantly extended median patient survival from 6.7 months to 13.2 months — nearly doubling it.
Pancreatic cancer (搜索), often referred to as the "king of cancers," carries a devastating prognosis. Data from China's National Cancer Center indicates a five-year survival rate of only approximately 7% to 9%. In the United States, the American Cancer Society's latest 2026 statistics show that the five-year relative survival rate for pancreatic cancer patients with distant metastasis is just 3%.
The U.S. Food and Drug Administration accepted the New Drug Application for daraxonrasib on July 22 for the treatment of previously treated metastatic pancreatic ductal adenocarcinoma. If approved, it would become the first truly effective RAS (搜索)-targeted therapy in the pancreatic cancer (搜索) field — a milestone described as the most significant advance in pancreatic cancer treatment in decades.
Combination Therapy Strategy
Under the agreement, the clinical collaboration will focus on combining BeiGene (搜索)'s two drug candidates — BGB-58067, a PRMT5 inhibitor, and BG-T187, an EGFRxMETxMET trispecific antibody — with either daraxonrasib (Pan-RAS (搜索)) or zoldonrasib (RAS G12D (搜索)) for the treatment of RAS-driven cancers.
Analysts at CICC noted that early data from Tango suggests PRMT5 inhibitors and RAS (搜索)(ON) inhibitors have combination potential in MTAP-deleted pancreatic cancers with concurrent RAS mutations. The partnership is expected to significantly accelerate BeiGene (搜索)'s development progress in this area.
Commercial Terms and Strategic Rationale
On the commercialization front, BeiGene (搜索) will pay development and sales milestone payments, as well as tiered royalties based on net sales. The company will also fund and lead a global registrational Phase 3 clinical trial for one of Revolution Medicines' RAS (搜索)(ON) inhibitors.
John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene (搜索), stated that this regional licensing agreement will fully leverage the company's global clinical development "fast-track" capabilities and established commercialization infrastructure to bring more treatment options to patients with refractory tumors.
CICC maintained an "Outperform" rating on BeiGene (搜索), with target prices set at CNY 340 (approximately $50.41) for A-shares, HK$266 (approximately $33.90) for Hong Kong-listed shares, and $445 for U.S. ADRs, implying potential upside ranging from 13% to 28%. The brokerage noted that the partnership reflects Revolution Medicines' high regard for BeiGene's commercialization capabilities in China and its global clinical development strength.
As RAS (搜索) inhibitors like daraxonrasib emerge as potential blockbuster drugs in the pancreatic cancer (搜索) field, paired with BeiGene (搜索)'s mature commercial network, this collaboration is expected to significantly boost the company's future revenue. Institutional investors believe BeiGene's clinical development "fast-track" strategy is accelerating its R&D speed in the solid tumor space, with the value of related molecules gradually being reflected in its market capitalization as subsequent clinical data is disclosed.